Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database
Urologia Internationalis · 15.10.2026 · 1-1
DOI: 10.1159/uin/aewag029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, online erschienen am 15.10.2026. Verfasst von Akihito Hashizume und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Urology and Renal transplantation, Yokohama City University Medical Center, Yokohama, Japan. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Introduction
Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy with a poor prognosis. Although adjuvant platinum-based chemotherapy is a standard treatment after radical nephroureterectomy (RNU), the efficacy of adjuvant nivolumab in UTUC remains unclear, especially in real clinical practice. We examined this using a large Japanese real-world database.
Methods
Using the Medical Data Vision database, we identified UTUC patients who underwent RNU and received adjuvant therapy. The adjuvant GC/GCarbo group and the adjuvant nivolumab group were defined by distinct treatment eras to reduce treatment selection bias. Event-free survival (EFS) was compared using Kaplan-Meier curves and the log-rank test, with a sensitivity analysis truncating follow-up at 300 days.
Results
A total of 1,058 patients were analyzed (240 nivolumab, 818 GC/GCarbo). In the whole cohort, EFS was significantly longer in the nivolumab group (HR = 0.6365, p = 0.0076). This association was consistent in patients with neoadjuvant chemotherapy (HR = 0.4053, p = 0.001) and in those without it (HR = 0.6765, p = 0.0462).
Conclusion
In Japanese UTUC patients, adjuvant nivolumab was associated with a longer EFS than GC/GCarbo. Because this was an unadjusted, observational comparison, the finding should be interpreted with caution and regarded as hypothesis-generating.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Urology and Renal transplantation, Yokohama City University Medical Center, Yokohama, Japan.
- Departments of Urology and Renal transplantation, Yokohama City University Medical Center, Yokohama, Japan, takashi_tk2001@yahoo.co.jp.
- Reproduction Center, Yokohama City University Medical Center, Yokohama, Japan.
- Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
Zitieren
APA
Hashizume, A., Kawahara, T., Yamazaki, M., Ueno, D., Kuroda, S., Takeshima, T., Takamoto, D., Noguchi, T., Yumura, Y., Uemura, H., Makiyama, K., & Teranishi, J. I. (2026). Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database. Urologia Internationalis, 1-1. https://doi.org/10.1159/uin/aewag029
Vancouver
Hashizume A, Kawahara T, Yamazaki M, Ueno D, Kuroda S, Takeshima T, et al. Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database. Urologia Internationalis. 2026:1-1. doi:10.1159/uin/aewag029
BibTeX
@article{Hashizume2026,
author = {Hashizume, Akihito and Kawahara, Takashi and Yamazaki, Masanobu and Ueno, Daiki and Kuroda, Shinnosuke and Takeshima, Teppei and Takamoto, Daiji and Noguchi, Takeaki and Yumura, Yasushi and Uemura, Hiroji and Makiyama, Kazuhide and Teranishi, Jun-Ichi},
title = {Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database},
journal = {Urologia Internationalis},
year = {2026},
pages = {1--1},
doi = {10.1159/uin/aewag029}
}
EUVIMED